This summary was created by AI, based on 1 opinions in the last 12 months.
CPRX is a biopharma company focused on developing drugs for rare diseases, with their drug for LEMS receiving approval but at a high cost. Revenues have been rising, but there is a ceiling due to the limited number of people with the disease. They have made acquisitions of the US rights for the drug Fycompa and a company that makes aGamree for another rare disease. However, there are concerns about the short patent protection period for their drugs and the approach of buying other companies instead of developing their own. Despite this, there is speculation about the company being taken over due to the hot market for rare disease companies.
Should be higher. They make a lot of money and beat their quarter.
Catalyst Pharmaceuticals is a American stock, trading under the symbol CPRX-Q on the NASDAQ (CPRX). It is usually referred to as NASDAQ:CPRX or CPRX-Q
In the last year, 2 stock analysts published opinions about CPRX-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Catalyst Pharmaceuticals.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Catalyst Pharmaceuticals published on Stockchase.
On 2024-03-28, Catalyst Pharmaceuticals (CPRX-Q) stock closed at a price of $15.89.
A biopharma that develops for rare diseases, such as LEMS for which CPRX's drug has received approval. But this trip costs US$360,000. Only insurance allows CPRX to charge such prices; revenues have been rising. But there's a ceiling, because there are a limited number of people afflicted with this disease. They bought US rights for the drug Fycompa, and bought a company that makes aGamree to treat another rare disease. An analyst believes the latter drug and feels shares can double. However, the firm Oppenheimer said that CPRX didn't need the money, and then the same firm was listed as a co-manager for a recent share offering. Result: shares dropped 15%. Last year, the CEO retired, and the CFO stepped down, so he thought CPRX may be sold, but the offering throws doubt on that. That said, rare disease companies are hot and so CPRX could be taken over. He doesn't like their business model: buying other companies and their drugs instead of developing their own. And their two drugs have patent protection for only a few more years--bad. There are better stocks in this space.